Ultragenyx gets FDA approval for GENGLYCOS gene therapy for GSDIa
Ultragenyx (RARE) announces U.S. FDA approval of GENGLYCOS™ gene therapy for glycogen storage disease type Ia (GSDIa), described as the first-ever FDA-approved treatment targeting the underlying cause.
Story updates
09:39:20 PM UTC
SquawkNews
RARE - PR: Ultragenyx Pharmaceutical Obtains FDA Accelerated Approval For GENGLYCOS In Adult And Pediatric Patients Eight Years And Older With Glycogen Storage Disease Type Ia GENGLYCOS is the first Gene therapy approval, and Fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of Care Associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to Host conference call on 8/19/26 at 6:00 P.M. Eastern Time
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.